![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1671878
¾à¹° ¿ëÃâ ½ºÅÙÆ® ½ÃÀå : Á¦Ç° À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°Drug Eluting Stents Market, By Product Type, By Application, By End User, By Geography |
¾à¹° ¿ëÃâ ½ºÅÙÆ® ¼¼°è ½ÃÀåÀº 2025³â¿¡ 84¾ï 9,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2025³âºÎÅÍ 2032³â±îÁö CAGR 8.7%·Î ¼ºÀåÇÏ¿© 2032³â¿¡´Â 152¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
º¸°í¼ ¹üÀ§ | º¸°í¼ »ó¼¼ | ||
---|---|---|---|
±âÁØ ¿¬µµ | 2024³â | 2025³â ½ÃÀå ±Ô¸ð | 84¾ï 9,000¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ | 2020-2024³â | ¿¹Ãø ±â°£ | 2025-2032³â |
¿¹Ãø ±â°£ : 2025-2032³â CAGR | 8.70% | 2032³â °¡Ä¡ ¿¹Ãø | 152¾ï 2,000¸¸ ´Þ·¯ |
¼¼°è ¾à¹° ¿ëÃâ ½ºÅÙÆ® ½ÃÀåÀº ½ÉÇ÷°üÁúȯÀÇ À¯º´·ü Áõ°¡¿Í °ü»óµ¿¸Æ Áúȯ ¹× µ¿¸ÆÆó»ö¿¡ Ãë¾àÇÑ ¼¼°è ³ëÀÎ Àα¸ÀÇ Áõ°¡·Î ÀÎÇØ Áö³ ¸î ³â°£ Å« ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ¾à¹° ¿ëÃâ ½ºÅÙÆ®´Â ³·Àº ÀçÇùÂø·ü µîÀÇ ÀåÁ¡À¸·Î ÀÎÇØ ÀÇ»çµéÀÌ º£¾î¸ÞÅ» ½ºÅÙÆ®º¸´Ù ¼±È£Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ºÅÙÆ® µðÀÚÀÎ ¹× ½ºÅÙÆ® Ç¥¸é¿¡ ÄÚÆÃµÈ ¾à¹°ÀÇ ±â¼úÀû Áøº¸·Î ÀÎÇØ ȯÀÚÀÇ ÀÓ»ó °á°ú°¡ °³¼±µÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª º£¾î¸ÞÅ» ½ºÅÙÆ®¿¡ ºñÇØ ¾à¹° ¿ëÃâ ½ºÅÙÆ®ÀÇ ³ôÀº ºñ¿ëÀÌ ½ÃÀå ¼ºÀå¿¡ Å« °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
¼¼°è ¾à¹° ¿ëÃâ ½ºÅÙÆ® ½ÃÀåÀº ³ëÀÎ Àα¸ÀÇ Áõ°¡, ½ÉÇ÷°üÁúȯÀÇ ºÎ´ã Áõ°¡, ÀçÇùÂø·ü °¨¼Ò µî º£¾î¸ÞÅ» ½ºÅÙÆ® ´ëºñ ¾à¹° ¿ëÃâ ½ºÅÙÆ®ÀÇ ¿ì¿ù¼º¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ¾à¹° ¿ëÃâ ½ºÅÙÆ®´Â º£¾î ¸ÞÅ» ½ºÅÙÆ®¿¡ ºñÇØ ºñ¿ëÀÌ ³ô¾Æ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ºÅÙÆ® ±â¼ú ¹× ¾à¹° ÄÚÆÃÀÇ ´Ù¾çÇÑ °³¹ßÀº ½ÃÀå Ç÷¹À̾°Ô À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, ÀÛ¿ë ÈÄ Ã¼³»¿¡¼ ¿ëÇØµÇ´Â »ýüÈí¼ö¼º ¾à¹° ¿ëÃâ ½ºÅÙÆ®´Â äÅÃÀÌ Áõ°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¸¶Âù°¡Áö·Î, ¾à¹° ºÐÀÚ¿ÍÀÇ °áÇÕ·ÂÀ» Çâ»ó½ÃŰ´Â ½ºÅÙÆ® Ç¥¸éÀÇ °³¹ßÀº ¾à¹° ¿ëÃ⠽ð£À» ´ÜÃàÇϰí Ä¡·á ºñ¿ëÀ» Àý°¨ÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.
¼¼°èÀÇ ¾à¹° ¿ëÃâ ½ºÅÙÆ® ½ÃÀåÀ» »ó¼¼È÷ ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) µ¿¾È ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR%)À» Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
¶ÇÇÑ ½ÃÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.
ÀÌ º¸°í¼´Â ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è ¾à¹° ¿ëÃâ ½ºÅÙÆ® ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» Á¦°øÇÕ´Ï´Ù.
ÁÖ¿ä ±â¾÷À¸·Î´Â Abbott Laboratories, Boston Scientific Corporation, Medtronic, Terumo Corporation, B. Braun Melsungen AG, C. R. Bard Inc., Cook Medical Inc., Biotronik SE & Co. KG, MicroPort Scientific Corporation, St. Jude Medical (now part of Abbott), Johnson & Johnson, Cardiovascular Systems Inc., Gore Medical, InspireMD, Asahi Intecc Co., Ltd., Z-Medica µîÀÌ ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
ÀÌ Á¶»ç º¸°í¼´Â ¾à¹° ¿ëÃâ ½ºÅÙÆ® ¼¼°è ½ÃÀåÀ» Á¶»çÇÏ¿© ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ÁøÀÔÀÚ, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ °ü°èÀÚ¿¡°Ô Á¦°øÇÕ´Ï´Ù.
ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ¾à¹° ¿ëÃâ ½ºÅÙÆ® ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.
Global Drug Eluting Stents Market is estimated to be valued at US$ 8.49 Bn in 2025 and is expected to reach US$ 15.22 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.7% from 2025 to 2032.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2024 | Market Size in 2025: | US$ 8.49 Bn |
Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: | 8.70% | 2032 Value Projection: | US$ 15.22 Bn |
The global drug eluting stents market has witnessed significant growth in the past few years owing to the rising prevalence of cardiovascular diseases and increasing geriatric population worldwide who are more prone to coronary heart diseases and artery blockages. Drug eluting stents are increasingly being preferred by physicians over bare metal stents due to advantages such as lower rates of restenosis. Moreover, technological advancements in design of stents and drugs coated on stent surfaces have improved clinical outcomes for patients. However, high costs of drug eluting stents compared to bare metal stents remain a major challenge for market growth.
The global drug eluting stents market is driven by the rising geriatric population, growing burden of cardiovascular diseases, and advantages offered by drug eluting stents over bare metal stents such as lower restenosis rates. However, the high costs of drug eluting stents compared to bare metal stents can hamper the market growth. Various developments in stent technology and drug coatings are expected to present lucrative opportunities for market players. For example, bioabsorbable drug eluting stents that dissolve in the body after performing their action could witness increasing adoption. Likewise, development of stent surfaces that enhance binding of drug molecules could help reduce drug elution times and costs of treatment.
This report provides in-depth analysis of the global drug eluting stents market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global drug eluting stents market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Abbott Laboratories, Boston Scientific Corporation, Medtronic, Terumo Corporation, B. Braun Melsungen AG, C. R. Bard Inc., Cook Medical Inc., Biotronik SE & Co. KG, MicroPort Scientific Corporation, St. Jude Medical (now part of Abbott), Johnson & Johnson, Cardiovascular Systems Inc., Gore Medical, InspireMD, Asahi Intecc Co., Ltd., and Z-Medica
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global drug eluting stents market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global drug eluting stents market